Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine

Panitumumab is a monoclonal antibody developed against the human epidermal growth factor receptor (EGFR). TAS‐102 is a novel chemotherapeutic agent containing trifluridine (FTD) as the active cytotoxic component. Both panitumumab and TAS‐102 have been approved for the treatment of metastatic colorec...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Yuji, Tamura, Toshiya, Satoh, Yoshihiko, Gotou, Masamitsu, Sawada, Hiroshi, Ebara, Shunsuke, Shibuya, Kazunori, Soeda, Jumpei, Nakamura, Kazuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537908/
https://www.ncbi.nlm.nih.gov/pubmed/28486761
http://dx.doi.org/10.1002/1878-0261.12074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537908/
https://www.ncbi.nlm.nih.gov/pubmed/28486761
http://dx.doi.org/10.1002/1878-0261.12074

Ejemplares similares